Sublingual Immunotherapy Outperforms Subcutaneous Allergoids in 2-Year Asthma Trial

In a 2-year prospective study, sublingual immunotherapy (SLIT) produced greater improvements in asthma control and inflammatory markers compared with subcutaneous allergoid immunotherapy.

“To compare the clinical effectiveness of sublingual immunotherapy (SLIT) versus subcutaneous allergoid immunotherapy,” investigators evaluated validated symptom scores and FeNO levels.

Among 180 patients, SLIT demonstrated superior improvements in ACT (+67.5% vs +44.2%, P=.00002) and FeNO reduction (–45.5% vs –30.8%, P=.00007). Regression analysis confirmed SLIT as an independent predictor of greater ACT improvement.

“SLIT demonstrated significantly greater improvements in asthma and rhinitis control, inflammatory biomarker reduction, and patient-reported outcomes compared to subcutaneous allergoid immunotherapy,” the authors concluded.

Reference

Prieto J, Martínez Tenopala R, González Uribe V, et al. Sublingual immunotherapy achieves greater asthma control than subcutaneous allergoids: a 2-year head-to-head trial. Presented at: American Academy of Allergy, Asthma, and Immunology annual meeting. February 27-March 2, 2026; Philadelphia, Pennsylvania.